Fig. 1: UNC1999 treatment triggers delayed activation of interferon response.

a Volcano plots showing the genes differential analysis statistics of UNC1999 (n = 3) versus UNC2400 at day 4 (left) and at day 6 (right) in BT16 cell line. The x axis represents the log₂FC of differential expression and the y axis represents the -log₁₀(FDR) of DEGs. Blue dots represent downregulated genes and red dots represent upregulated genes. Black dots represent genes that are not significantly differentially expressed. Significance was determined by |log 2FC| > 1 and FDR < 0.05. Negative binomial likelihood ratio test with BH (Benjamini–Hochberg)-corrected for multiple testing. b–d Gene ontology (GO) analysis of significantly upregulated genes in UNC1999 versus UNC2400 at day 4 (b), UNC1999 versus UNC2400 at day 6 (c), and UNC1999 at day 6 versus day 4 (d). Precision represents the overlap between the tested genes and the gene set of the terms. P-value is calculated by the one-sided hypergeometric test followed by correction for multiple testing. e Analysis of transcription factor binding site enrichments for upregulated genes in UNC1999 versus UNC2400 at day 4 (left) and day 6 (right). P-value is calculated by the hypergeometric test followed by correction for multiple testing. f The expression of selected interferon-responsive genes in four indicated ATRT cell lines with either UNC2400 or UNC1999 treatment was measured by quantitative real-time PCR at day 6. g The CHLA02 (left) or BT16 (right) cell line was treated with UNC1999 in the presence or absence of the JAK1/JAK2 inhibitor Ruxolitinib (1 μM) or the JAK3 inhibitor CP-690550 (1 μM). The expression of four indicated interferon-responsive genes was measured by quantitative real-time PCR at day 6. Data are mean ± SD of three biologically independent replicates; P-value is calculated by multiple unpaired t tests (two-tailed) followed by correction for multiple testing (f, g). Source data are provided as a Source Data file.